FDA Approves Icotrokinra, First Oral Targeted Peptide for Plaque Psoriasis
The FDA has approved icotrokinra, the first oral targeted peptide for plaque psoriasis, adding a new formulation category to the systemic therapy options dermatologists can prescribe.